biocrea expands management team
This article was originally published in Scrip
Executive Summary
German CNS therapeutics company, biocrea GmbH, a management buy-out from Finland's Biotie Therapies, has expanded its management team by appointing Dr Martin Gunthorpe as Chief Scientific Officer, Mr Viktor Viehweg to the position of Chief Financial Officer, and Professor Simon Ward to Executive Vice President Chemistry & Development. Dr Gunthorpe joins biocrea from GlaxoSmithKline, where he was Head of Electrophysiology and Project Leader in the Neurosciences Centre of Excellence for Drug Discovery. Professor Ward also joins biocrea from GSK, where he has been Assistant Director and a member of business unit & chemistry leadership teams, he also holds the Chair of Medicinal Chemistry at the University of Sussex, UK. Mr Viehweg was most recently Head of Corporate Strategy at Moscow-based Sibur Ltd.